SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.
COVID-19
Multiple sclerosis
SARS-CoV-2
Vaccination
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
03 Nov 2023
03 Nov 2023
Historique:
received:
07
07
2023
accepted:
28
09
2023
revised:
26
09
2023
medline:
3
11
2023
pubmed:
3
11
2023
entrez:
3
11
2023
Statut:
aheadofprint
Résumé
COVID-19 vaccines have been recommended to people with multiple sclerosis (pwMS) and, to ensure durable immunity, a third booster dose has been administered in several countries. Data about potential risks associated with the third booster dose in pwMS, such as vaccine-triggered disease exacerbations, are still scarce. To investigate whether the administration of a third booster dose of mRNA COVID-19 vaccines was associated with an increased risk of short-term disease reactivation in a large cohort of pwMS. We retrospectively selected 1265 pwMS who received a third booster dose of an mRNA COVID-19 vaccine. Demographic and clinical data were collected, including the presence, number and characteristics of relapses in the 60 days prior to and after the third booster dose. In the selected cohort, the relapse rate in the two months after administration of the third booster dose of mRNA COVID-19 vaccines did not increase when compared with the prior two months. Indeed, the percentage of pwMS experiencing relapses in the 60 days following the administration of the third booster dose was 2.1%, similar to the percentage recorded in 60 days prior to vaccination, which was 1.9%. The third booster dose of mRNA COVID-19 vaccines appeared to be safe for pwMS.
Sections du résumé
BACKGROUND
BACKGROUND
COVID-19 vaccines have been recommended to people with multiple sclerosis (pwMS) and, to ensure durable immunity, a third booster dose has been administered in several countries. Data about potential risks associated with the third booster dose in pwMS, such as vaccine-triggered disease exacerbations, are still scarce.
OBJECTIVE
OBJECTIVE
To investigate whether the administration of a third booster dose of mRNA COVID-19 vaccines was associated with an increased risk of short-term disease reactivation in a large cohort of pwMS.
METHODS
METHODS
We retrospectively selected 1265 pwMS who received a third booster dose of an mRNA COVID-19 vaccine. Demographic and clinical data were collected, including the presence, number and characteristics of relapses in the 60 days prior to and after the third booster dose.
RESULTS
RESULTS
In the selected cohort, the relapse rate in the two months after administration of the third booster dose of mRNA COVID-19 vaccines did not increase when compared with the prior two months. Indeed, the percentage of pwMS experiencing relapses in the 60 days following the administration of the third booster dose was 2.1%, similar to the percentage recorded in 60 days prior to vaccination, which was 1.9%.
CONCLUSIONS
CONCLUSIONS
The third booster dose of mRNA COVID-19 vaccines appeared to be safe for pwMS.
Identifiants
pubmed: 37922069
doi: 10.1007/s00415-023-12034-0
pii: 10.1007/s00415-023-12034-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Shih HI, Wu CJ, Tu YF, Chi CY (2020) Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines. Biomed J 43(4):341–354. https://doi.org/10.1016/j.bj.2020.05.021 . (PMID: 32532623)
doi: 10.1016/j.bj.2020.05.021
pubmed: 32532623
pmcid: 7260535
Golob JL, Lugogo N, Lauring AS, Lok AS (2021) SARS-CoV-2 vaccines: a triumph of science and collaboration. JCI Insight 6(9):e149187. https://doi.org/10.1172/jci.insight.149187 . (PMID: 33822773)
doi: 10.1172/jci.insight.149187
pubmed: 33822773
pmcid: 8262277
Polack FP, Thomas SJ, Kitchin N, et al. C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–2615. doi: https://doi.org/10.1056/NEJMoa2034577 . PMID: 33301246.
Baden LR, El Sahly HM, Essink B, et al; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384 (5):403–416. doi: https://doi.org/10.1056/NEJMoa2035389 . PMID: 33378609.
Karussis D, Petrou P (2014) The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev 13(3):215–224. https://doi.org/10.1016/j.autrev.2013.10.003 . (PMID: 24514081)
doi: 10.1016/j.autrev.2013.10.003
pubmed: 24514081
Zrzavy T, Kollaritsch H, Rommer PS et al (2019) Vaccination in multiple sclerosis: friend or foe? Front Immunol 10:1883. https://doi.org/10.3389/fimmu.2019.01883 . (PMID: 31440255)
doi: 10.3389/fimmu.2019.01883
pubmed: 31440255
pmcid: 6693409
Rakusa M, Öztürk S, Moro E, et al (2022) European Academy of Neurology NeuroCOVID-19 Task Force. COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper. Eur J Neurol 29 (8): 2163–2172. doi: https://doi.org/10.1111/ene.15368 . PMID: 35460319.
Cabreira V, Abreu P, Soares-Dos-Reis R et al (2021) Multiple sclerosis, disease-modifying therapies and COVID-19: a systematic review on immune response and vaccination recommendations. Vaccines (Basel) 9(7):773. https://doi.org/10.3390/vaccines9070773 . (PMID: 34358189)
doi: 10.3390/vaccines9070773
pubmed: 34358189
Achiron A, Dolev M, Menascu S et al (2021) COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by february 2021. Mult Scler 27(6):864–870. https://doi.org/10.1177/13524585211003476 . (PMID: 33856242)
doi: 10.1177/13524585211003476
pubmed: 33856242
pmcid: 8114441
Lotan I, Wilf-Yarkoni A, Friedman Y et al (2021) Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel. Eur J Neurol 28(11):3742–3748. https://doi.org/10.1111/ene.15028 . (PMID: 34288285)
doi: 10.1111/ene.15028
pubmed: 34288285
pmcid: 8444776
Di Filippo M, Cordioli C, Malucchi S, et al (2022) RIREMS (Rising Researchers in MS) group. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. J Neurol Neurosurg Psychiatry 93 (4): 448–450. doi: https://doi.org/10.1136/jnnp-2021-327200 . PMID: 34408003.
Epstein S, Xia Z, Lee AJ, et al. (2022) Multiple Sclerosis Resilience to COVID-19 (MSReCOV) Collaborative Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data. Mult Scler Relat Disord 57: 103433. Doi: https://doi.org/10.1016/j.msard.2021.103433 . PMID: 34923427.
Ciampi E, Uribe-San-Martin R, Soler B et al (2022) Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with multiple sclerosis. Mult Scler Relat Disord 59:103690. https://doi.org/10.1016/j.msard.2022.103690 . (PMID: 35182880)
doi: 10.1016/j.msard.2022.103690
pubmed: 35182880
pmcid: 8842089
Czarnowska A, Tarasiuk J, Zajkowska O et al (2022) Safety of Vaccines against SARS-CoV-2 among polish patients with multiple sclerosis treated with disease-modifying therapies. Vaccines (Basel) 10(5):763. https://doi.org/10.3390/vaccines10050763 . (PMID: 35632519)
doi: 10.3390/vaccines10050763
pubmed: 35632519
Kong L, Wang X, Chen H et al (2022) Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis. Mult Scler Relat Disord 68:104167. https://doi.org/10.1016/j.msard.2022.104167 . (PMID: 36170773)
doi: 10.1016/j.msard.2022.104167
pubmed: 36170773
pmcid: 9472679
Maniscalco GT, Manzo V, Di Battista ME et al (2021) Severe multiple sclerosis relapse after COVID-19 vaccination: a case report. Front Neurol 12:721502. https://doi.org/10.3389/fneur.2021.721502 . (PMID: 34447349)
doi: 10.3389/fneur.2021.721502
pubmed: 34447349
pmcid: 8382847
Nistri R, Barbuti E, Rinaldi V et al (2021) Case report: multiple sclerosis relapses after vaccination against SARS-CoV2: a series of clinical cases. Front Neurol 12:765954. https://doi.org/10.3389/fneur.2021.765954 . (PMID: 34744992)
doi: 10.3389/fneur.2021.765954
pubmed: 34744992
pmcid: 8569136
Quintanilla-Bordás C, Gascón-Gimenez F, Alcalá C et al (2022) Case report: exacerbation of relapses following mRNA COVID-19 vaccination in multiple sclerosis: a case series. Front Neurol 13:897275. https://doi.org/10.3389/fneur.2022.897275 . (PMID: 35572939)
doi: 10.3389/fneur.2022.897275
pubmed: 35572939
pmcid: 9091902
Rinaldi V, Bellucci G, Buscarinu MC et al (2022) CNS inflammatory demyelinating events after COVID-19 vaccines: a case series and systematic review. Front Neurol 13:1018785. https://doi.org/10.3389/fneur.2022.1018785 . (PMID: 36530641)
doi: 10.3389/fneur.2022.1018785
pubmed: 36530641
pmcid: 9752005
Levin EG, Lustig Y, Cohen C et al (2021) Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 Months. N Engl J Med 385(24):e84. https://doi.org/10.1056/NEJMoa2114583 . (PMID: 34614326)
doi: 10.1056/NEJMoa2114583
pubmed: 34614326
Capuano R, Bisecco A, Conte M et al (2022) Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod. Mult Scler Relat Disord 60:103724. https://doi.org/10.1016/j.msard.2022.103724 . (PMID: 35272145)
doi: 10.1016/j.msard.2022.103724
pubmed: 35272145
pmcid: 8895707
Bar-On YM, Goldberg Y, Mandel M et al (2021) Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med 385(15):1393–1400. https://doi.org/10.1056/NEJMoa2114255 . (PMID: 34525275)
doi: 10.1056/NEJMoa2114255
pubmed: 34525275
Capuano R, Prosperini L, Altieri M et al (2023) Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs. Mult Scler 29(7):856–865. https://doi.org/10.1177/13524585231167515 . (PMID: 37165941)
doi: 10.1177/13524585231167515
pubmed: 37165941
pmcid: 10183344
König M, Torgauten HM, Tran TT et al (2022) Immunogenicity and safety of a Third SARS-CoV-2 vaccine dose in patients with multiple sclerosis and weak immune response after COVID-19 Vaccination. JAMA Neurol 79(3):307–309. https://doi.org/10.1001/jamaneurol.2021.5109 . (PMID: 35072702)
doi: 10.1001/jamaneurol.2021.5109
pubmed: 35072702
pmcid: 8787678
Capuano R, Altieri M, Conte M et al (2022) Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod. J Neurol 269(12):6185–6192. https://doi.org/10.1007/s00415-022-11296-4 . (PMID: 35879563)
doi: 10.1007/s00415-022-11296-4
pubmed: 35879563
pmcid: 9314242
Dreyer-Alster S, Menascu S, Mandel M et al (2022) COVID-19 vaccination in patients with multiple sclerosis: safety and humoral efficacy of the third booster dose. J Neurol Sci 434:120155. https://doi.org/10.1016/j.jns.2022.120155 . (PMID: 35091386)
doi: 10.1016/j.jns.2022.120155
pubmed: 35091386
pmcid: 8779784
Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173. https://doi.org/10.1016/S1474-4422(17)30470-2 . (PMID: 29275977)
doi: 10.1016/S1474-4422(17)30470-2
pubmed: 29275977
Ehde DM, Roberts MK, Humbert AT et al (2021) COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: a follow up survey during the initial vaccine rollout in 2021. Mult Scler Relat Disord 54:103163. https://doi.org/10.1016/j.msard.2021.103163 . (PMID: 34325399)
doi: 10.1016/j.msard.2021.103163
pubmed: 34325399
pmcid: 8295053
Stastna D, Menkyova I, Drahota J et al (2022) To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection. Mult Scler Relat Disord 65:104014. https://doi.org/10.1016/j.msard.2022.104014 . (PMID: 35803085)
doi: 10.1016/j.msard.2022.104014
pubmed: 35803085
pmcid: 9250417
Frahm N, Fneish F, Ellenberger D et al (2023) Frequency and predictors of relapses following SARS-CoV-2 vaccination in patients with multiple sclerosis: interim results from a longitudinal observational study. J Clin Med 12(11):3640. https://doi.org/10.3390/jcm12113640 . (PMID: 37297838)
doi: 10.3390/jcm12113640
pubmed: 37297838
pmcid: 10254005
Stefanou MI, Palaiodimou L, Theodorou A, et al. (2023) Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis. Mult Scler. 13524585221150881. doi: https://doi.org/10.1177/13524585221150881 . PMID: 36722184.
Bertozzi A, Mariottini A, Marchi L et al (2023) Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: a monocentric experience. Mult Scler Relat Disord 72:104582. https://doi.org/10.1016/j.msard.2023.104582 . (PMID: 36889098)
doi: 10.1016/j.msard.2023.104582
pubmed: 36889098
pmcid: 9957336
Farez MF, Correale J (2011) Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol 258(7):1197–1206. https://doi.org/10.1007/s00415-011-5984-2 . (PMID: 21431896)
doi: 10.1007/s00415-011-5984-2
pubmed: 21431896
Buljevac D, Flach HZ, Hop WC et al (2002) Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125(Pt 5):952–960. https://doi.org/10.1093/brain/awf098 . (PMID: 11960885)
doi: 10.1093/brain/awf098
pubmed: 11960885